Skip to contentP
Pulse Biosciences, Inc.
P
PLSEPulse Biosciences, Inc. Q3 2024 · 10-Q
Revenue$0.00$0.00— vs Q3 2023 Net Income-$12.68M-$12.68MN/M vs Q3 2023 EPS, diluted—
Operating Income-$13,655,000N/M Operating Cash Flowderived-$9,024,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pulse Biosciences, Inc. · CIK 1625101 · Engraved from SEC EDGAR
Free Cash Flowderived-$9,062,000N/M ended Sep 30, 2024 · filed Oct 30, 2024 · 30 d after period end